Navigation Links
Deep-water discovery

Last December, University of Miami Rosenstiel School of Marine and Atmospheric Science researchers using advanced sonar techniques discovered new deepwater reef sites in the Straits of Florida between Miami and Bimini. Today through May 30, the Rosenstiel School scientists will work with Harbor Branch Oceanographic Institution colleagues to explore these areas for the first time. The expedition, which will rely on Harbor Branch's Johnson-Se-Link II submersible, will search for and collect marine organism samples from these new reefs in 2,000-2,900 feet of water to determine which produce chemicals with the potential to treat human diseases such as cancer or Alzheimer's disease. The State of Florida's "Florida Oceans Initiative" is the primary project funder.

"The reef raises important issues and questions," said Dr. Mark Grasmueck, a Rosenstiel School professor. "How a reef like this sustains itself without sunlight, without obvious energy and nourishment--it's a unique ecosystem. I find myself putting aside other work to pursue this further as I see this as a once-in-a-lifetime opportunity."

Researchers have suspected since the 1970s that deep reefs lay undiscovered between Miami and Bimini because pieces of reef-building corals had been brought up using surface-operated, dredge-and-grab sampling equipment. However, just as the vast majority of the ocean remains poorly mapped and unexplored ?even off Miami ?these potentially important areas remained unseen.

In December 2005, as part of the NOAA Ocean Exploration program, Rosenstiel School researchers, led by Professors Grasmueck and Gregor Eberli, began mapping deepwater habitats off Miami and Bimini using advanced sonar technology and an autonomous underwater vehicle (AUV). AUVs operate without a tether to the surface and are pre-programmed to independently perform tasks. These researchers believe this is the first time an AUV has been used for mapping deepwater coral reefs. AUVs ha
'"/>

Source:University of Miami Rosenstiel School of Marine & Atmospheric Science


Page: 1 2 3

Related biology news :

1. Purdue proves concept of using nano-materials for drug discovery
2. Leprosy microbes lead scientists to immune discovery
3. Harmless virus may hold key to more effective HIV drug discovery
4. Biota makes major antiviral discovery
5. Research updates 65-year-old genetic discovery
6. Pest control research leads to pain control discovery
7. One-of-a-kind imaging probe reveals secrets useful for drug discovery
8. Unicellular microRNA discovery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Deep water discovery

(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9Hormones May Affect Neurological Disease Risk 50513 1Hormones May Affect Neurological Disease Risk 50513 2Antibiotics May Boost Risk for Recurrent Ear Infection 50511 1Antibiotics May Boost Risk for Recurrent Ear Infection 50511 2
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
X-GAL (5-Bromo-4-Chloro-3-Indolyl-Beta-D-Galactopyranoside), = 99.0% from AMRESCO, Inc.
Custom Peptide Synthesis from Raybiotech, Inc.
DTNB from Cayman Chemical
Keyhole Limpet Hemocyanin NP-KLH (Keyhole Limpet Hemocyanin), Unconjugated from Biosearch Technologies
Biology Products: